Nemolizumab
Based on 1 Customer Validation
Nemolizumab (CIM331) is a humanized monoclonal antibody that targets the human interleukin-31 receptor a, preventing interleukin-31 (IL-31) from binding to its receptor and the subsequent signaling. Nemolizumab can help reduce itching and sleep disturbances, and it is being studied for atopic dermatitis (AD).
For research use only. We do not sell to patients.
- Purity : 99.70%
- CAS No.: 1476039-58-3
- Molecular Weight:144.92 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Isotype
Human IgG2 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
IL-31Ra
In Vitro
Nemolizumab (0.01-100 ng/mL, 2 d) inhibits the IL-31-dependent proliferation of Ba/F3 cells overexpressing
hIL-31RA/cyIL-31RA and OSMR β[3].
Nemolizumab (0.01-100 ng/mL, 2 h pretreatment + 20 min co-incubation) inhibits hIL-31 (30 ng/mL)-induced STAT3 phosphorylation in A549 cells does dependently[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Nemolizumab (1 mg/kg, s.c., acute administration) exerts a mean plasma concentration of 1490 ng/mL at Day 56 in 5 of 6 experiment cynomolgus monkeys and suppresses the scratching behaviour from shortly after administration until Day 56[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG2 kappa
Application
ELISA, FACS, Functional assay
Verified Bioactivity
Chemical Information
-
CAS No. 1476039-58-3
-
Appearance Liquid
-
Molecular Weight 144.92 kDa
-
Color Colorless to light yellow
-
SMILES
[Nemolizumab]
-
Synonyms
CIM331; CD14152
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[2]. O Nemoto, et al. The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study. Br J Dermatol. 2016 Feb;174(2):296-304. [Content Brief]
[3]. Oyama S, et al. Cynomolgus monkey model of interleukin-31-induced scratching depicts blockade of human interleukin-31 receptor A by a humanized monoclonal antibody. Exp Dermatol. 2018 Jan;27(1):14-21. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)